Pacira BioSciences (PCRX)
(Real Time Quote from BATS)
$27.07 USD
+0.12 (0.45%)
Updated May 2, 2024 11:50 AM ET
4-Sell of 5 4
A Value B Growth D Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PCRX 27.07 +0.12(0.45%)
Will PCRX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PCRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PCRX
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag
PCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues
Here's What Key Metrics Tell Us About Pacira (PCRX) Q4 Earnings
Pacira (PCRX) Matches Q4 Earnings Estimates
Other News for PCRX
Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
Commit To Buy Pacira BioSciences At $17.50, Earn 10.4% Annualized Using Options
Noteworthy Tuesday Option Activity: PCRX, CMG, CVNA
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 6 Analysts
Understanding Key Factors Behind Pacira Pharmaceuticals’ Analyst Rating